Person in charge: Dr. Marc-Emmanuel Dumas
Metabolic disorders and cardiovascular complications are multifactorial diseases resulting from the strong interaction between lifestyle factors such as nutrition, drug treatments or physical activity, the microbiome and the human host genome.
From the metabolomic, metagenomic and epigenomic data generated by the clinical studies of PreciDIAB and the partner studies, our objective to assess the impact of nutrition, medication and lifestyle on (cardio) metabolic diseases, in particular of particular interest to the role played by the microbiome and its metabolites as mediators.
We thus wish to provide new hypotheses on the spectrum of cardiometabolic diseases that we will validate in the PreciDIAB cohorts by a holistic approach of the links between lifestyle, microbiome and cardiometabolic risk